PCR Technologies Market by Technology (Real-time PCR (qPCR), Digital PCR (dPCR), Reverse Transcription PCR (RT-PCR), Hot-start PCR, and Other PCR); Product (Reagents and Consumables, Instruments, Software and Services); Application (Clinical Application, Research Application, and Forensic Application); End User (Hospitals and Diagnostic Centers, Pharmaceutical and Biotechnology Companies, and Academic and Research Institutions), and Geography: Global Market Size Estimates and Forecast (2022-2030)

Code: BMIRE00027069 | Pages: 100 | Industry: Biotechnology | Date: Oct 2022 | Type: Global

The market crossed the US$ 7.5 billion mark in 2022 and is expected to hit US$ 10.0 billion by 2030, recording a CAGR of 6.5% during the forecast period.

The PCR technologies market has been significantly growing with the increase in the prevalence of inflammatory bowel diseases.

Diseases, particularly inflammatory bowel, colorectal, and bladder cancer, require ostomy surgeries as they involve the surgical removal of the tumor or some part of the intestine. Whereas, in some incidences, the surgical opening is made through the abdomen to make a new pathway for the waste removal process, called an ostomy. For instance, according to recent data from WHO, in 2020, colon and rectal cancer cases are the fifth and eighth most frequently occurring cancers globally. In 2021, the real-time PCR segment held the maximum share in the market, whereas the digital PCR segment is expected to grow with high CAGR rates during the forecast period.  

Within the report, the market is segmented into technology, product, application, end user, and geography.  Based on technology, the market is segmented into real-time PCR (qPCR), digital PCR (dPCR), reverse transcription PCR (RT-PCR), hot-start PCR, and other PCR. On the basis of product, the market is categorized as reagents and consumables, instruments, and software and services. On the basis of application, the market is segmented into clinical application, research application, forensic application. On the basis of end user, the market is categorized as hospitals and diagnostic centers, pharmaceutical and biotechnology companies, and academic and research institutions. Geographically, the market is sub segmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

Get more information on this report :

Rising investments from pharmaceutical companies will provide future opportunity

Polymerase chain reaction (PCR) is a vital technology in recombination DNA technology required for the in-vitro amplification of the gene. Several variations of the technology are available to support PCR testing, which consists of thermal cyclers, gradient PCR machines, PCR workstations and cabinets, and qPCR machines. Moreover, it is also used to create thousands to millions of duplicates of specific DNA grouping and explore diseases such as AIDS, tuberculosis, and middle ear diseases. It has been used for a long  time as the standard technique for research studies on nucleic acids in labs. 

Huge investments from pharmaceutical giants and biotechnology industries are expected to propel the market's growth during the forecast period. The key players in the company are developing portable, fast, convinient instruments for point-of-care settings. For example, in July 2021, QuantuMDx launched the Q-POC system, which offers rapid POC molecular diagnostics advantages for settings, such as ICUs, clinics, and birthing centers. In addition, various POC polymerase chain reaction tests have received approval in the last two years for the detection of COVID-19 disease.

Surge in prevalence of infectious diseases is one of the major factors accelerating market growth.

The demand for PCR technologies has significantly increased with the prevalence of infectious diseases. PCR technologies have shown to be effective in diagnosing several infectious diseases, such as COVID-19, influenza, and others. For instance, according to the data from Wolrdometer, approximately 236 million COVID-19 cases have been diagnosed till October 2021. Apart from this, PCR technologies have also been applied for the rapid diagnosis of pulmonary tuberculosis, driving the market's growth during the forecast period. 

Recent strategic developments in the PCR technologies market

The PCR technologies market has undergone several significant developments, and a few of these have been mentioned below:

  • In June 2022, Cephied collaborated with BioGX to deliver a PCR test for Monkeypox that will run on the GeneXpert system.
  • In October 2021, US based Thermo Fisher Scientific, provider of scientific instrumentation, reagents and consumables, introduced the Applied Biosystem QuantStudio Absolute Q-Digital PCR System, the first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results in genetic analysis and research within 90 minutes.
  •  In March 2021, Agilent Technologies Inc., announced the launch of a real-time reverse transcription (qRT) PCR-based diagnostic kit to detect SARS-CoV-2 RNA. 

Several players drive the PCR technologies market by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. Thermo Fisher Scientific, Inc., F. Hoffman-La Roche Ltd., Bio-Rad Laboratories, Inc., QIAGEN N.V., and Takara Bio, Inc.; Agilent Technologies, Inc., bioMérieux S.A. (France), Fluidigm Corporation are among the prominent players operating in the market.

Target audience for the report:

  • Drug developing companies
  • Contract development and manufacturing organization,
  • Drug discovery-related associations, organizations, forums, and alliances
  • Government bodies, such as regulating authorities and policymakers
  • Venture capitalists, private equity firms, and start-up companies
  • Drug distributors and sales firms
  • End users of drug discovery
  • Research institutes, organizations, and consulting companies

Scope of the report:

In this report, the market has been segmented on the basis of:

  • Technology:
    • Real-time PCR (qPCR)
    • Digital PCR (dPCR)
    • Reverse Transcription PCR (RT-PCR)
    • Hot-Start PCR
    • Other PCR
  • Product:
    • Reagents and Consumables
    • Instruments
    • Software and Service
  • Application:
    • Clinical Application
    • Research Application
    • Forensic Application
  • End User:
    • Hospitals and Diagnostic Centers
    • Pharmaceutical and Biotechnology Companies
    • Academic Research Institutes
  • Region
    • North America
    • Europe
    • Asia Pacific (APAC)
    • South & Central America
    • Middle East & Africa
  • Companies profiled
  • Thermo Fisher Scientific Inc.
  • Takara Bio Inc.
  • Fluidigm Corporation
  • F. Hoffmann-LA Roche AG
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Biomerieux S.A.
  • LGC Limited
  • Qiagen N.V.
  • Promega Corporation

The List of Companies
- Thermo Fisher Scientific Inc.
- Takara Bio Inc.
- Fluidigm Corporation
- F. Hoffmann-LA Roche AG
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc.
- Biomerieux S.A.
- LGC Limited
- Qiagen N.V.
- Promega Corporation


Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$1500
Site License
$2500
Enterprise License
$3500